Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine as Consolidation Strategy in LBCL After CAR T-cell Therapy
NCT05464719Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2022
- Primary completion
- Jan 2030
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2022; status: recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05464719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05464719.